Navigation Links
Labopharm to present at Cowen 30th Annual Health Care Conference
Date:3/3/2010

LAVAL, QC, March 3 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place, on Tuesday, March 9, 2010 at 1:30 p.m. ET.

Interested parties may access the live webcast for this presentation by visiting the "Events" section of the homepage of the Company's website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.

About Labopharm Inc.

Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. Its second product, OLEPTRO(TM), a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. The Company also has a pipeline of follow-on products in both pre-clinical and clinical development.

SOURCE Labopharm Inc.

Back to top
'/>"/>
SOURCE Labopharm Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm announces underwriters exercise of over-allotment option for recent public offering
2. Labopharm announces closing of US$20 million public offering of units
3. Labopharm announces pricing of US$20 million public offering of units
4. Labopharm settles $1 million draw down under standby equity distribution agreement
5. Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
6. Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
7. Labopharm Reports Results for Third Quarter Fiscal 2009
8. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
9. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
10. Labopharm submits response to FDA for novel antidepressant
11. Labopharm Reports Results for Second Quarter Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... G.A. (PRWEB) , ... February 09, 2016 , ... ... and grout cleaning and sealing company , is proud to announce that many ... their superior levels of customer service. The hard surface restoration franchises received customer ...
(Date:2/8/2016)... , ... February 08, 2016 , ... CURE Media ... has officially launched the Multiple Myeloma Heroes Awards event , which will annually ... the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
(Date:2/8/2016)... New York, NY (PRWEB) , ... February 08, 2016 , ... ... handles are too much to handle, you are not alone. According to the Center ... conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency Dennis ... FL area, has initiated a fundraiser for a two year old little girl ... after Christmas. To support this beautiful child who is facing life’s journey without ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... 2016 Respiratory Devices - Medical Devices ... Devices sector report, " Respiratory Devices - Medical ... of Respiratory Devices currently in pipeline stage. ... products with comparative analysis of the products at ... players involved in the pipeline product development. It ...
Breaking Medicine Technology: